Subsequently, we divided our cohort into two primary groups: the first group consisted of ER-positive tumors (n = 1,175), while the second group comprised triple-negative breast cancers (n = 400), characterized by the absence of ER, PR, and HER2/neu receptor expression. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.